Table 3.
Pooled results of acquired T790M detection rates in the A + T and TKI alone groups.
| Study | Treatment arm | Test samples | Test methods | Test cases (n) | Cases of T790M (n) | T790M rate | Pooled T790M rate | RR/P value (A + T vs. TKI) |
|---|---|---|---|---|---|---|---|---|
| NEJ026 [13, 25] | Bev + Erl | Plasma | (PNA-LNA) PCR clamp | 42 | 8 | 19% | A + T 30.4% (95% CI: 21.7–39.1%) vs. TKI 34.6% (95% CI: 27.3–42%) | RR = 0.967 (95% CI: 0.668–1.358), P = 0.846 |
| Erl | Plasma | (PNA-LNA) PCR clamp | 45 | 11 | 20.8% | |||
| Bev + Erl | Tissue | (PNA-LNA) PCR clamp | 7 | 4 | 57.1% | |||
| Erl | Tissue | (PNA-LNA) PCR clamp | 9 | 4 | 44.4% | |||
| RELAY [15] | Ram + Erl | Plasma | NGS-360 | 44 | 19 | 43% | ||
| Erl | Plasma | NGS-360 | 75 | 35 | 47% | |||
| CTONG1509 [14] | Bev + Erl | Tissue | NGS-448 | 6 | 2 | 33% | ||
| Erl | Tissue | NGS-448 | 12 | 5 | 42% |
Bev: bevacizumab; Erl: erlotinib; Ram: ramucirumab; NGS: next-generation sequencing; RR: relative risk ratios; TKI: tyrosine kinase inhibitor; A + T: angiogenic inhibitors combined with TKI; PNA-LNA PCR clamp: peptide nucleic acid locked nucleic acid polymerase chain reaction clamp.